移行细胞癌患者人附睾蛋白的表达水平及其与肿瘤学特征的关联性

Clinical expression of human epididymal protein 4 in migratory cell carcinoma and its association with oncologic features

目的研究人附睾蛋白4(HE4)在移行细胞癌(TCC)患者中的临床表达水平及其与肿瘤学特征的关联性。方法选取2015年6月至2017年5月间于东莞市厚街医院泌尿外科住院接受手术治疗的泌尿系统TCC患者60例为TCC组,泌尿系统良性疾病患者60例为良性组,体检结果健康的60例为对照组。检测三组受检者的HE4水平并进行对比分析。结果 TCC组患者的HE4表达水平为(279.87±18.92)pmol/L,明显高于良性组的(77.69±8.35)pmol/L和对照组的(68.32±7.72)pmol/L,差异均有统计学意义(P<0.05),而良性组和对照组HE4水平比较差异均无统计学意义(P>0.05);HE4在非肌层浸润性TCC患者中的阳性率为83.3%,明显高于良性组23.3%和对照组15.0%,差异均有统计学意义(P<0.05);TCC组不同年龄、性别、体重、病理分期分级、肿瘤数量和位置间比较,HE表达阳性率差异均无统计学意义(P>0.05)。结论 HE4的表达水平和TCC患者的肿瘤学特征间无关联性,但其在移行细胞癌患者中的表达和阳性率显著增高,且非肌层浸润性移行细胞癌患者的HE4表达和阳性率也显著增高,这一特异性表明HE4可以作为移行细胞癌的早期诊断和监测指标。

Objective To investigate the clinical expression of human epididymal protein 4 （HE4） in patientswith transitional cell carcinoma （TCC） and its association with oncologic features. Methods Sixty patients with TCCin the urinary system in Department of Urology, Houjie Hospital of Dongguan City from June 2015 to May 2017 wereselected as TCC group, and 60 patients with benign urological diseases were selected as benign group. Another 60 sub-jects with healthy physical examination results were enrolled as the control group. HE4 levels in three groups were de-tected and compared. Results HE4 expression level in TCC group was （279.87±18.92） pmol/L, which was significant-ly higher than （77.69±8.35） pmol/L in the benign group and （68.32±7.72） pmol/L in the control group （P〈0.05）. The be-nign group and control group showed no statistically significant in HE4 levels （P〉0.05）. The positive rate of HE4 innon-muscle invasive TCC was 83.3%, which was significantly higher than 23.3% in the benign group and 15.0% in thecontrol group （P〈0.05）. There were no significant differences in the positive rates of HE expression in TCC group be-tween different age, sex, weight, pathological stage, tumor quantity and location （P〉0.05）. Conclusion There was nocorrelation between the expression level of HE4 and the oncologic characteristics of TCC patients, but the expressionand positive rate of HE4 in patients with TCC were significantly increased, especially in non-muscle invasive TCC pa-tients, which shows that HE4 can be used as an indicator for early diagnosis and monitoring of TCC.